{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  St John's wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  acalabrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  aceclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950320_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  aceclofenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  alprostadil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  anagrelide  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  aspirin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  axitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">Bemiparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bemiparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">benzydamine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  benzydamine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   bevacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  bosutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">bromfenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  bromfenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">enhance</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">MHRA advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bupropion   might   enhance   the risk of serotonin syndrome when given with   dapoxetine .  MHRA advises monitor .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950342_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Bupropion   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   cabozantinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  cangrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"caplacizumab\" outputclass=\"int-drug\">caplacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   caplacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caplacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  celecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950347_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  celecoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  cilostazol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cinacalcet\" outputclass=\"int-drug\">Cinacalcet</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cinacalcet   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinacalcet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950353_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  clopidogrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   cobimetinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">Crizotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Crizotinib   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">Cyproheptadine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cyproheptadine   potentially   decreases   the effects of   dapoxetine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dalteparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  dasatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  dexketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950366_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  dexketoprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  diclofenac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950367_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  diclofenac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  dipyridamole  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950373_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950373_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Both  dapoxetine  and  duloxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">eicosapentaenoic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  eicosapentaenoic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enoxaparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  epoprostenol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">Eptifibatide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eptifibatide   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Erythromycin   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  etodolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950382_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  etodolac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  etoricoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950383_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  etoricoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">fenfluramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  fenfluramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">Fluoxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluoxetine   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  flurbiprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950388_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  flurbiprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin\" outputclass=\"int-drug\">Heparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Heparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ibrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ibuprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950399_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  ibuprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  iloprost  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  imatinib  can increase the risk of bleeding.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950402_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950403_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  indometacin  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950405_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  indometacin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   inotersen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ketoprofen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950411_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  ketoprofen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ketorolac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950412_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  ketorolac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  lenvatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  mefenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950419_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  mefenamic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  meloxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950420_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  meloxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of prolonged neuromuscular blockade when given with</ph> <ph otherprops=\"mivacurium\" outputclass=\"int-drug\">mivacurium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   potentially   increases   the risk of prolonged neuromuscular blockade when given with   mivacurium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mivacurium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  nabumetone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950427_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  nabumetone  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  naproxen  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950428_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  naproxen  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">Nilotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Nilotinib   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  nintedanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">omega-3-acid ethyl esters</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  omega-3-acid ethyl esters  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of adverse effects when given with</ph> <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">ozanimod</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   might   increase   the risk of adverse effects when given with   ozanimod .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  parecoxib  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950439_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  parecoxib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">Paroxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Paroxetine   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  pazopanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  phenazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950444_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  phenazone  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  piroxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950447_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  piroxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">ponatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ponatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  prasugrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  regorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  sorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  sulindac  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950463_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  sulindac  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  sunitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Unknown\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of prolonged neuromuscular blockade when given with</ph> <ph otherprops=\"suxamethonium\" outputclass=\"int-drug\">suxamethonium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Unknown",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   potentially   increases   the risk of prolonged neuromuscular blockade when given with   suxamethonium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Suxamethonium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">Tapentadol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of serotonin syndrome when given with</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tapentadol   is predicted to   increase   the risk of serotonin syndrome when given with   dapoxetine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tenoxicam  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950469_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  tenoxicam  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"terbinafine\" outputclass=\"int-drug\">Terbinafine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Terbinafine   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbinafine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tiaprofenic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950471_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  tiaprofenic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  ticagrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">Tirofiban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tirofiban   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tolfenamic acid  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950476_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  tolfenamic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   trametinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   trastuzumab emtansine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  treprostinil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950489_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  venlafaxine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate CYP3A4 inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate CYP3A4 inhibitors .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">Dapoxetine</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"volanesorsen\" outputclass=\"int-drug\">volanesorsen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid depending on platelet countconsult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dapoxetine   causes   bleeding, as can   volanesorsen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises avoid depending on platelet countconsult product literature .    \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Volanesorsen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid potent CYP3A4 inhibitors or adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   moderately   increase   the exposure to   dapoxetine .  Manufacturer advises avoid potent CYP3A4 inhibitors or adjust  dapoxetine  dose .    \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950493_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  dapoxetine  and  vortioxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2#bnf_i1643857950496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"dapoxetine\" outputclass=\"int-heading-drug\">dapoxetine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  dapoxetine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under Antidepressant drugs in BNF for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				}
			],
			"hasSearchLabel": " Dapoxetine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/dapoxetine-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Dapoxetine </title>"
			},
			"rdfs:label": "dapoxetine"
		}
	]
}